Park Eun Jung, Je Jihyun, Dusabimana Theodomir, Yun Seung Pil, Kim Hye Jung, Kim Hwajin, Park Sang Won
Department of Pharmacology, Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju 52727, Republic of Korea.
Department of Convergence Medical Sciences, Gyeongsang National University Graduate School, Jinju 52727, Republic of Korea.
Int J Mol Sci. 2023 Feb 8;24(4):3413. doi: 10.3390/ijms24043413.
Renal ischemia reperfusion (IR) injury is a major cause of acute kidney injury (AKI) that is often complicated by multiple organ failure of the liver and intestine. The mineralocorticoid receptor (MR) is activated in patients with renal failure associated with glomerular and tubular damage. We thus investigated whether canrenoic acid (CA), a mineralocorticoid receptor (MR) antagonist, protects against AKI-induced hepatic and intestinal injury, suggesting the underlying mechanisms. Mice were divided into five groups: sham mice, mice subjected to renal IR, and mice pretreated with canrenoic acid (CA; 1 or 10 mg/kg) 30 min prior to renal IR. At 24 h after renal IR, the levels of plasma creatinine, alanine aminotransferase and aldosterone were measured, and structural changes and inflammatory responses of the kidney, liver, and intestine were analyzed. We found that CA treatment reduced plasma creatinine levels, tubular cell death and oxidative stress induced by renal IR. CA treatment also decreased renal neutrophil infiltration and inflammatory cytokine expression and inhibited the release of high-mobility group box 1 induced by renal IR. Consistently, CA treatment reduced renal IR-induced plasma alanine transaminase, hepatocellular injury and neutrophil infiltration, and inflammatory cytokine expression. CA treatment also decreased small intestinal cell death, neutrophil infiltration and inflammatory cytokine expression induced by renal IR. Taken together, we conclude that MR antagonism by CA treatment protects against multiple organ failure in the liver and intestine after renal IR.
肾缺血再灌注(IR)损伤是急性肾损伤(AKI)的主要原因,常并发肝和肠的多器官功能衰竭。盐皮质激素受体(MR)在伴有肾小球和肾小管损伤的肾衰竭患者中被激活。因此,我们研究了盐皮质激素受体(MR)拮抗剂坎利酮酸(CA)是否能预防AKI诱导的肝和肠损伤,并阐明其潜在机制。将小鼠分为五组:假手术小鼠、接受肾IR的小鼠以及在肾IR前30分钟用坎利酮酸(CA;1或10mg/kg)预处理的小鼠。肾IR后24小时,测量血浆肌酐、丙氨酸转氨酶和醛固酮水平,并分析肾、肝和肠的结构变化和炎症反应。我们发现,CA治疗可降低血浆肌酐水平、肾小管细胞死亡以及肾IR诱导的氧化应激。CA治疗还可减少肾中性粒细胞浸润和炎症细胞因子表达,并抑制肾IR诱导的高迁移率族蛋白B1释放。同样,CA治疗可降低肾IR诱导的血浆丙氨酸转氨酶水平、肝细胞损伤、中性粒细胞浸润和炎症细胞因子表达。CA治疗还可减少肾IR诱导的小肠细胞死亡、中性粒细胞浸润和炎症细胞因子表达。综上所述,我们得出结论,CA治疗通过拮抗MR可预防肾IR后肝和肠的多器官功能衰竭。